Combination of anlotinib and Tislelizumab for lung adenocarcinoma: effects on metabolic and flora microenvironment and exploration of prognosis-related biomarkers
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP457392
下载链接
链接失效反馈官方服务：
资源简介：
To investigate the specific mechanism of action of the immune checkpoint inhibitor tislelizumab in combination with anlotinib in the treatment of lung adenocarcinoma from the perspectives of immune cells, cytokines, intestinal flora, metabolomics, etc., so as to provide a basis for better individualized and comprehensive treatment.
创建时间：
2023-08-31
